Loading
Ponsegromab is a monoclonal antibody from Pfizer, in registered phase 3 trials for pancreatic ductal adenocarcinoma.
Ponsegromab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 3 trial sponsored by Pfizer, in pancreatic ductal adenocarcinoma. A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below.
1.Ponsegromab binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Ponsegromab" OR ABSTRACT:"Ponsegromab") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ponsegromab, not a curated reading list.
Shares Pfizer (incl. Seagen) and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pfizer (incl. Seagen) and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma and the tags pipeline, registry-only.